Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients
Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this open label study is to evaluate the safety, tolerability,
pharmacokinetics, and efficacy of AZD1208 in patients with recurrent or refractory Acute
Myelogenous Leukemia (AML). This study will have two parts. In Part A, patients will receive
escalating doses to identify the maximum tolerated dose (MTD). In Part B, the efficacy of the
maximum tolerated dose will be evaluated in a expanded group of patients.